The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from France have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases.
The EFFI-CLIN project, of which the company HISTALIM is a partner, aims to offer a new cancer immunotherapy adapted to the immunological profile of each tumor according to the concept of personalized medicine by targeting a new generation of immune checkpoints.
The PYTHEAS NAVIGATION project, led by the company of the same name, aims to develop a second generation surgical navigation device for spine surgery, simple to use, compact, affordable and reducing patients' exposure to X-rays. Supported and certified by Eurobiomed, funded by the World Innovation Competition (CMI phase 2 – 2017), the project closed successfully in December 2021.
Do you accept the deposit and reading of cookies to allow us to analyze your browsing anonymously and measure the audience of our website?OuiNonPrivacy Policy
You can revoke your consent at any time using the “Revoke Consent” button.Revoke consent
